ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

Easy Qualification For Low-Cost Semaglutide Weight Loss Injections: 2025 Update

The new two-minute assessment allows patients to qualify for regular semaglutide injections, which are prescribed by doctors at LiveGood Clinic and shipped to locations nationwide.

-- LiveGood Clinic announced the qualification assessment to improve access to affordable semaglutide for weight loss, even as new research published in the New England Journal of Medicine (NEJM) points to its benefits for those suffering from metabolic dysfunction-associated steatohepatitis (MASH)—a potentially fatal liver disease caused by the accumulation of excess fat in the liver.

For more information, visit http://bigbenefits.info/fdameds

The FDA has approved semaglutide—a GLP-1 agonist—for overweight patients with a BMI of 27 or more suffering from at least one weight-related condition or patients with obesity whose BMI exceeds 30. With the rise in demand for brand-name GLP-1 agonists like Ozempic, Wegovy, and Rybelus, LiveGood offers its members semaglutide injections at a monthly cost of $179—$120 cheaper than competing clinics and pharmacies and $300 to $900 cheaper than the brand-name alternatives. Membership is priced at $9.95 monthly and $99.95 annually.

LiveGood Clinic's assessment is quick and discreet, with most applicants approved almost immediately. Sometimes, the clinic may review an application to ensure patient safety. Once a patient qualifies for the treatment, their dosage is adjusted, and the first dose is shipped to their address. Based on the doctor's evaluation, the starting weekly dose can vary from 0.1 to 0.15 mg and can be titrated over several weeks to up to 0.3 to 0.5 mg.

The clinic notes the exceptional efficacy of semaglutide in aiding weight loss, citing an NEJM study confirming that participants taking semaglutide lost an average of 14.9% of their body weight after 68 weeks compared to 2.4% with placebo. Patients also showed improvements in other health markers, including blood pressure, lipid profiles, and waist circumference. The medication works by delaying stomach emptying, sustaining a feeling of satiety, reducing appetite, and increasing insulin release.

"If you've considered using Semaglutide to jumpstart your weight loss journey, or if you're looking to save on your current prescription, LiveGood Clinic is here to help," said a spokesperson for the clinic. "Join thousands of satisfied members who are achieving their weight loss goals and improving their health."

LiveGood members can also access the brand's nutritional supplement store and supplement marketing business opportunity.

For more information about medical weight loss with semaglutide, visit http://bigbenefits.info/fdameds

Contact Info:
Name: Mitzy Dadoun
Email: Send Email
Organization: Love It Reviews
Address: 63 Songbird Cres, Lindsay, on k9v0a9, Canada
Website: https://www.loveitreviews.com/

Source: NewsNetwork

Release ID: 89161316

Should you identify any discrepancies, concerns, or inaccuracies in the content provided in this press release or require assistance with a press release takedown, we strongly urge you to notify us promptly by contacting error@releasecontact.com (it is important to note that this email is the authorized channel for such matters, sending multiple emails to multiple addresses does not necessarily help expedite your request). Our responsive team is committed to addressing your concerns within 8 hours by taking necessary actions to resolve identified issues diligently or guiding you through the necessary steps for removal. Our dedication lies in providing accurate and reliable information.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.